The Effect of Linagliptin (BI 1356) on 24h-glucose Control and Various Biomarkers in Type 2 Diabetic Patients
Primary Purpose
Diabetes Mellitus, Type 2
Status
Completed
Phase
Phase 2
Locations
Germany
Study Type
Interventional
Intervention
Placebo (linagliptin)
Placebo (linagliptin)
Sitagliptin
Placebo (sitagliptin)
Placebo (sitagliptin)
Linagliptin
Sponsored by

About this trial
This is an interventional treatment trial for Diabetes Mellitus, Type 2
Eligibility Criteria
Inclusion criteria:
- Male and female patients with a diagnosis of type 2 diabetes mellitus and previously treated with not more than one drug
- Glycosylated haemoglobin A1 (HbA1c) 6.5 to 10.0% at Start of Run-in
Exclusion criteria:
- Myocardial infarction, stroke or transient ischemic attack "TIA" within 6 months prior to informed consent
- Impaired hepatic function
- Renal insufficiency with a creatinine clearance < 50 mL/min
- Treatment with rosiglitazone, pioglitazone, glucagon like peptide 1 (GLP-1) analogues, insulin, dipeptidyl peptidase 4 (DPP-4) inhibitors or anti-obesity drugs 3 months prior to informed consent.
Sites / Locations
- 1218.37.49003 Boehringer Ingelheim Investigational Site
- 1218.37.49002 Boehringer Ingelheim Investigational Site
- 1218.37.49001 Boehringer Ingelheim Investigational Site
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Placebo Comparator
Experimental
Active Comparator
Arm Label
Placebo
Linagliptin
Sitagliptin
Arm Description
Patients received placebo matching 5mg linagliptin and placebo matching 100mg sitagliptin.
Patients received 5mg linagliptin, and placebo matching 100mg sitagliptin.
Patients received 100mg sitagliptin, and placebo matching 5mg linagliptin.
Outcomes
Primary Outcome Measures
Weighted Mean Glucose (WMG) Change From Baseline at Day 28
The change from baseline reflects the day 28 WMG value minus the baseline WMG value. Means are treatment adjusted for baseline HbA1c, previous anti-diabetic medication, and baseline WMG.
GLP-1 (Glucagon Like Peptide 1) AUEC (0-2h) (Area Under Effect Curve) Change From Baseline at Day 28
The change from baseline reflects the day 28 GLP-1 AUEC (0-2h) value minus the baseline GLP-1 AUEC (0-2h) value. Means are treatment adjusted for baseline HbA1c, previous anti-diabetic medication and baseline GLP-1.
Secondary Outcome Measures
Fasting Plasma Glucose (FPG) Change From Baseline at Day 28
The change from baseline reflects the day 28 FPG value minus the baseline FPG value. Means are treatment adjusted for baseline HbA1c, previous anti-diabetic medication and baseline FPG.
Plasma Glucose Area Under Effect Curve (AUEC) (0-3h) Change From Baseline at Day 28
The change from baseline reflects the day 28 Glucose AUEC (0-3h) value minus the baseline Glucose AUEC (0-3h) value. Means are treatment adjusted for baseline HbA1c, previous anti-diabetic medication and baseline plasma glucose AUEC (0-3h).
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT00716092
Brief Title
The Effect of Linagliptin (BI 1356) on 24h-glucose Control and Various Biomarkers in Type 2 Diabetic Patients
Official Title
A 4-week, Randomized, Double Blind, Double Dummy, Placebo Controlled, Parallel Group Study Comparing the Influence of BI 1356 (5 mg) and Sitagliptin (100 mg) Administered Orally Once Daily on Various Biomarkers in Type 2 Diabetic Patients
Study Type
Interventional
2. Study Status
Record Verification Date
January 2014
Overall Recruitment Status
Completed
Study Start Date
July 2008 (undefined)
Primary Completion Date
November 2008 (Actual)
Study Completion Date
undefined (undefined)
3. Sponsor/Collaborators
Name of the Sponsor
Boehringer Ingelheim
4. Oversight
5. Study Description
Brief Summary
The objective of this study is to investigate the effect of BI 1356 on 24-h glucose control and various pharmacodynamic parameters in type 2 diabetic patients with inadequate glycaemic control.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes Mellitus, Type 2
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
Double
Allocation
Randomized
Enrollment
121 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Patients received placebo matching 5mg linagliptin and placebo matching 100mg sitagliptin.
Arm Title
Linagliptin
Arm Type
Experimental
Arm Description
Patients received 5mg linagliptin, and placebo matching 100mg sitagliptin.
Arm Title
Sitagliptin
Arm Type
Active Comparator
Arm Description
Patients received 100mg sitagliptin, and placebo matching 5mg linagliptin.
Intervention Type
Drug
Intervention Name(s)
Placebo (linagliptin)
Intervention Description
once daily for 28 days
Intervention Type
Drug
Intervention Name(s)
Placebo (linagliptin)
Intervention Description
once daily for 28 days
Intervention Type
Drug
Intervention Name(s)
Sitagliptin
Intervention Description
100 mg once daily for 28 days
Intervention Type
Drug
Intervention Name(s)
Placebo (sitagliptin)
Intervention Description
once daily for 28 days
Intervention Type
Drug
Intervention Name(s)
Placebo (sitagliptin)
Intervention Description
once daily for 28 days
Intervention Type
Drug
Intervention Name(s)
Linagliptin
Intervention Description
5mg once daily for 28 days
Primary Outcome Measure Information:
Title
Weighted Mean Glucose (WMG) Change From Baseline at Day 28
Description
The change from baseline reflects the day 28 WMG value minus the baseline WMG value. Means are treatment adjusted for baseline HbA1c, previous anti-diabetic medication, and baseline WMG.
Time Frame
Baseline and day 28
Title
GLP-1 (Glucagon Like Peptide 1) AUEC (0-2h) (Area Under Effect Curve) Change From Baseline at Day 28
Description
The change from baseline reflects the day 28 GLP-1 AUEC (0-2h) value minus the baseline GLP-1 AUEC (0-2h) value. Means are treatment adjusted for baseline HbA1c, previous anti-diabetic medication and baseline GLP-1.
Time Frame
Baseline and day 28
Secondary Outcome Measure Information:
Title
Fasting Plasma Glucose (FPG) Change From Baseline at Day 28
Description
The change from baseline reflects the day 28 FPG value minus the baseline FPG value. Means are treatment adjusted for baseline HbA1c, previous anti-diabetic medication and baseline FPG.
Time Frame
Baseline and day 28
Title
Plasma Glucose Area Under Effect Curve (AUEC) (0-3h) Change From Baseline at Day 28
Description
The change from baseline reflects the day 28 Glucose AUEC (0-3h) value minus the baseline Glucose AUEC (0-3h) value. Means are treatment adjusted for baseline HbA1c, previous anti-diabetic medication and baseline plasma glucose AUEC (0-3h).
Time Frame
Baseline and day 28
Other Pre-specified Outcome Measures:
Title
Exploratory Sensitivity Analysis of the WMG Change From Baseline at Day 28
Description
The change from baseline reflects the day 28 WMG value minus the baseline WMG value. Means are treatment adjusted for baseline HbA1c, previous anti-diabetic medication and baseline WMG.
Time Frame
Baseline and day 28
Title
Exploratory Sensitivity Analysis of GLP-1 AUEC (0-2h) Change From Baseline at Day 28
Description
The change from baseline reflects the day 28 GLP-1 AUEC (0-2h) value minus the baseline GLP-1 AUEC (0-2h) value. Means are treatment adjusted for baseline HbA1c, previous anti-diabetic medication and baseline GLP-1.
Time Frame
Baseline and day 28
Title
Exploratory Sensitivity Analysis of FPG Change From Baseline at Day 28
Description
The change from baseline reflects the day 28 FPG value minus the baseline FPG value. Means are treatment adjusted for baseline HbA1c, previous anti-diabetic medication and baseline FPG.
Time Frame
Baseline and day 28
Title
Exploratory Sensitivity Analysis of Plasma Glucose AUEC (0-3h) Change From Baseline at Day 28
Description
The change from baseline reflects the day 28 FPG value minus the baseline FPG value. Means are treatment adjusted for baseline HbA1c, previous anti-diabetic medication and baseline FPG.
Time Frame
Baseline and day 28
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion criteria:
Male and female patients with a diagnosis of type 2 diabetes mellitus and previously treated with not more than one drug
Glycosylated haemoglobin A1 (HbA1c) 6.5 to 10.0% at Start of Run-in
Exclusion criteria:
Myocardial infarction, stroke or transient ischemic attack "TIA" within 6 months prior to informed consent
Impaired hepatic function
Renal insufficiency with a creatinine clearance < 50 mL/min
Treatment with rosiglitazone, pioglitazone, glucagon like peptide 1 (GLP-1) analogues, insulin, dipeptidyl peptidase 4 (DPP-4) inhibitors or anti-obesity drugs 3 months prior to informed consent.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Boehringer Ingelheim
Organizational Affiliation
Boehringer Ingelheim
Official's Role
Study Chair
Facility Information:
Facility Name
1218.37.49003 Boehringer Ingelheim Investigational Site
City
Berlin
Country
Germany
Facility Name
1218.37.49002 Boehringer Ingelheim Investigational Site
City
Mainz
Country
Germany
Facility Name
1218.37.49001 Boehringer Ingelheim Investigational Site
City
Neuss
Country
Germany
12. IPD Sharing Statement
Links:
URL
http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/1218/1218.37_U09-2397.pdf
Description
Related Info
Learn more about this trial
The Effect of Linagliptin (BI 1356) on 24h-glucose Control and Various Biomarkers in Type 2 Diabetic Patients
We'll reach out to this number within 24 hrs